J.P. Morgan Healthcare Conference 2021 - Kevin Hrusovsky, Chairman, CEO & President January 13, 2021 - Investor Relations ...
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
J.P. Morgan Healthcare Conference 2021 Kevin Hrusovsky, Chairman, CEO & President January 13, 2021
Forward-Looking Statements & Non-GAAP Financial Measures
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such
as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing
future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements include the
Company’s estimated Q4 and full year 2020 financial performance, which is preliminary and unaudited and is subject to completion of the
Company’s normal quarter and year-end close procedures. These procedures and the audit of the Company’s financial statements for the
year ended December 31, 2020 are ongoing and could result in changes to such estimated information. Forward-looking statements in this
news release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking
statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the
forward-looking statements in this press release are discussed in Quanterix’ filings with the U.S. Securities and Exchange Commission,
including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-
looking statements contained herein to reflect any change in expectations, even as new information becomes available.
To supplement the Company’s financial statements presented on a GAAP basis, the Company has provided certain non-GAAP financial
measures. Management uses these non-GAAP measures to evaluate the Company’s operating performance in a manner that allows for
meaningful period-to-period comparison and analysis of trends in its business. Management believes that such measures are important in
comparing current results with prior period results, and are useful to investors and financial analysts in assessing the Company’s operating
performance. The non-GAAP financial information presented here should be considered in conjunction with, and not as a substitute for the
financial information presented in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP
measures to their most directly comparable GAAP financial measures set forth in the appendix of this presentation.
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 2
Today’s Agenda
Vision and Strategy 2020 Compelling Powering Proteomics
for Disruptive Value Progress Precision Health Disruption
• Di5 Methodology • COVID PIVOT • Neuro
Catalyzing
Precision Health
• Proteomics Leadership • RUO-Dx Highway • COVID
Transformation
• Research + Diagnostics • Enabling AD Drugs • Immunology
• Leapfrog to Payors • Ecosystem Catalyzed • Disruption
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 3
VISION AND STRATEGY FOR DISRUPTIVE VALUE CREATION
Compelling Thesis to Lead Proteomics into Precision Health Era
Execution Aspiration
2 to 3x Value Creation 10 to 15x Value Creation
RESEARCH & DISCOVERY D I A G N O S T I C S & H E A LT H S C R E E N S
$1B to $20B TAM $100B TAM
Validation: Pubs, Trials, Pharma Adoption Abbott, Siemens, Pharma Advances
2014-20 Rev: $0 - $85m; 55% CAGR* - Public Payor Acceptance for Cost / Outcome
COVID
Raised $350m; Valuation $30m to $2.0 B RADx NIH, RADx & FDA Ecosystem expansion
ST & LT Growth Catalysts ST & LT Growth Catalysts
• Increase penetration Neuro, COVID, Immuno • COVID EUA’s
• Menu expansion & drug / population trials • Neuro Tool Entry – Leverage COVID
• Scale consumables growth – New COO • Liquid Biopsy Entry (Partner or Vertical)
• Expand into upstream Discovery tools • Advance Payor “Outcome Leapfrog”
* 2017-2020 3Yr CAGR
* FY 2020 information are preliminary, unaudited estimates and are subject to the Company’s normal quarter
and year-end close procedures. These procedures and the audit of the Company’s financial statements for J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 4
the year ended December 31, 2020 are ongoing and could result in changes to such estimated information.
VISION AND STRATEGY FOR DISRUPTIVE VALUE CREATION
Simoa® provides insight into Health to Disease Continuum
H E A LT H A S Y M P T O M AT I C SICK CARE
CONCENTRATION
BIOMARKER
BIOPSY
SYMPTOMS
SICKNESS BEGINS
SPINAL TAP
IMAGING cancer
I N VA S I V E N E S S
Current neuro
detection
cardio
GOAL infectious
disease
covid-19
BLOOD
SALIVA
URINE S TA G E O F I N T E R V E N T I O N
H E A LT H Y E A R LY D I S E A S E L AT E D I S E A S E D E AT H
BIOMARKER
Current detection CONCENTRATION
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 5
VISION AND STRATEGY FOR DISRUPTIVE VALUE CREATION
Simoa® provides insight into Health to Disease Continuum
H E A LT H A S Y M P T O M AT I C SICK CARE
CONCENTRATION
BIOMARKER
BIOPSY
SYMPTOMS
SICKNESS BEGINS
SPINAL TAP
IMAGING
I N VA S I V E N E S S
Current
detection
cancer
cardio
neuro
GOAL infectious
New disease
detection covid-19
BLOOD
SALIVA
URINE S TA G E O F I N T E R V E N T I O N
H E A LT H Y E A R LY D I S E A S E L AT E D I S E A S E D E AT H
BIOMARKER
New detection Current detection CONCENTRATION
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 6
VISION AND STRATEGY FOR DISRUPTIVE VALUE CREATION
Proteins Predictive of Health
CONTENT UTILITY
Cataloged variants
High High utility but low
accessibility of accessibility of
content but low content
utility
Genome Transcriptome Proteome
22,000 genes 100,000+ proteins
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 7
VISION AND STRATEGY FOR DISRUPTIVE VALUE CREATION
Proteins Predictive of Health
CONTENT UTILITY
Cataloged variants
High High utility but low
accessibility of accessibility of
content but low content
utility
Genome Transcriptome Proteome
22,000 genes 100,000+ proteins
Static over time Environmental triggers Dynamic, real-time
Identical Twins Identical Twins
Diet Stress Lifestyle Pollution Infections Radiation Drugs
Poor Diet Smoker
Health pre-disposition Diabetes Cancer
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 8
VISION AND STRATEGY FOR DISRUPTIVE VALUE CREATION
Digital Biomarkers Sensitivity Unlocking Proteomics
Research Clinical LATE : INVASIVE
1300 Proteins 200 Proteins
Nanograms/mL
Detection
limits
Femtograms/mL Research Clinical
100,000 1000
Proteins 1000 to 100,000x Proteins
More sensitive EARLY : NON-INVASIVE
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 9
VISION AND STRATEGY FOR DISRUPTIVE VALUE CREATION
Disruption in sensitivity catalyzing TAM expansion & reallocation
Greater sensitivity
enables…
Less invasive, smaller samples
New biomarkers & subtypes
Multiplexing for disease specificity
Single molecule to unravel
heterogeneity
…which changes the
healthcare paradigm:
Early detection
E A R LY Health to disease continuum
Homecare & frequent testing
LOW S E N S I T I V I T Y HIGH Disease progression monitoring
CURRENT NEW DETECTION LIMIT Prevention, costs & outcomes
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 10J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 11
Megatrends in Healthcare Catalyzing
Proteomics for Precision Health
Rise of Employee, Student Prevention Inclusion
Home Care & Entertainment & Asymptomatic & Equity
Immunology
Proteomics Disruption Decentralized Trials
& Viral Mutations
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 12VISION AND STRATEGY FOR DISRUPTIVE VALUE CREATION
TAM evolution
2020 2021 2022 2023 2024 2025 2026 2027
Pre-COVID:
Research
Created Neurology Tools
Foray into Immunology
Market Segments Low share High share Cumulative TAM
Research Diagnostics &
& Trials Health Screens
Neurology 0.4 B
COVID
Immunology
& Oncology 0.7 B
$1B
1.1 B 0B
TAMs based on LEK Estimates and Report 2020 J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 13VISION AND STRATEGY FOR DISRUPTIVE VALUE CREATION
TAM evolution
2020 2021 2022 2023 2024 2025 2026 2027
Pre-COVID: Post-COVID:
Research Accelerated Dx
Created Neurology Tools COVID Dx accelerates Neuro entry
Foray into Immunology Deepen Immunology research
Market Segments Low share High share Cumulative TAM
Research Diagnostics &
& Trials Health Screens
Neurology 0.4 B 18 B
COVID 0.2 B 12 B $32B
Immunology
& Oncology 1.1 B
$1B
Remaining TAM in
Other TAs 2B 30 B
TAMs other than COVID and Neurology Dx Opportunity based on LEK Estimates and Report 2020 J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 14
COVID and Neurology Dx Opportunity based on Health Advances Estimates and Report 2020VISION AND STRATEGY FOR DISRUPTIVE VALUE CREATION
TAM evolution
2020 2021 2022 2023 2024 2025 2026 2027
Pre-COVID: Post-COVID: Disruptive growth:
Research Accelerated Dx PPH Megatrends
Created Neurology Tools COVID Dx accelerates Neuro entry Proteomics liquid biopsy platform
Foray into Immunology Deepen Immunology research Trial decentralization & health screens
Market Segments Low share High share Cumulative TAM
Research Diagnostics &
& Trials Health Screens
Neurology 0.9 B 18 B $64B
COVID 0.7 B 13 B $32B
Immunology
& Oncology 4.0 B 25 B
$1B
Remaining TAM in
Other TAs 7B 57 B
TAMs other than COVID and Neurology Dx Opportunity based on LEK Estimates and Report 2020 J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 15
COVID and Neurology Dx Opportunity based on Health Advances Estimates and Report 2020VISION AND STRATEGY FOR DISRUPTIVE VALUE CREATION
TAM evolution
2020 2021 2022 2023 2024 2025 2026 2027
Pre-COVID: Post-COVID: Disruptive growth: Visionary:
Research Accelerated Dx PPH Megatrends Proteomic Revolution
Created Neurology Tools COVID Dx accelerates Neuro entry Proteomics liquid biopsy platform Move upstream to catalyze biomarker
discovery and increase protein flow
Foray into Immunology Deepen Immunology research Trial decentralization & health screens
Market Segments Low share High share Cumulative TAM
Discovery & Diagnostics & $120B
Research Health Screens
Neurology $64B
COVID 20B 100B $32B
Immunology
& Oncology
$1B
TAMs other than COVID and Neurology Dx Opportunity based on LEK Estimates and Report 2020 J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 16
COVID and Neurology Dx Opportunity based on Health Advances Estimates and Report 2020VISION AND STRATEGY FOR DISRUPTIVE VALUE CREATION
Near term priorities to catalyze & fortify proteomics leadership
COVID Vertical Commercialize COVID EUA’s
Fulfilment Drive Leading-Edge research including long-hauler research
Convert research into Novel Differentiated Commercial Applications
Neurology Launch novel neuro multiplex; expand clinical trials and China
Vertical Continue Accelerator expansion and add Neurology Drug rescue
Launch Nf-L MS Minimum Residual Disease monitoring, Leverage Pharma data
Clinically validate AD pre-symptomatic screening and develop AD triage through pharma partnerships
Immunology Launch new immunology & oncology biomarkers
Expansion Position SP-X as platform of choice for proteomics liquid biopsy
Disrupt Expand Payor Relationships for Health Screens – OUTCOME LEAPFROG
Precision Health Leverage Pharma and Payor relationships to expand DECENTRALIZED CLINICAL TRIALS
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 172020 COMPELLING PROGRESS
2020 Compelling Progress: Record Growth, Adoption & Value Ascent
COVID Neurology
Serology & Antigen EUA’s Launched pTau-181
181 & Neuro panel
RADx $20 million, NIH/FDA ties Alzheimer’s drug trials momentum
Payor Adoption – Population studies MS Drug approvals with NfL
Leading-edge research & capability ~48% HD-Fleet is HD-X & GROWTH
Record publications & funding Abbott License Agreement
Platform
100x Sensitivity pilot success Lab Services Expansion & Growth
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 182020 COMPELLING PROGRESS
Scientific Validation driving Adoption
PUBLICATIONS BIOMARKERS INSTRUMENTS ACCELERATOR
Cumulative Cumulative Placements Projects & Revenue
Neurology 1,120 # of units placed $m Revenue 132
403 535
Immunology & Oncology Cumulative
100 32 48 Number of Drug
Infectious Diseases Trial Projects
Others 31 101 18.0
117
322
106 2.1
400
240
259
677
45
278 8.1
244
190 10.0
18
409 7.7
133 4
176 381 0
663
120 4.9
206
3.1 7.8
53 71
104 96
56 1.1
15 16 17 18 19 20 15 16 17 18 19 20 15 16 17 18 19 20 15 16 17 18 19 20*
Preliminary
* Q4 2020 and FY 2020 information are preliminary, unaudited estimates and are subject to the Company’s normal quarter and
year-end close procedures. These procedures and the audit of the Company’s financial statements for the year ended December J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 19
31, 2020 are ongoing and could result in changes to such estimated information.2020 COMPELLING PROGRESS
Superb Execution Continues
REVENUE $m
Strategic Growth Q4 Approx.
Approx.
+50% 84 to 86
Public Co
Indicators Performance
3YR CAGR
+20%
24
to
Approx.
67 to 69 +57%
GAAP 55% +51% 26
Non-GAAP 44%
20
Approx.
Increase in Accelerator revenue 56.7
80%
Approximate*
2019 to 2020, driven by immunology 22
to
+32%
+64% 15.9
Proportion of HD-Fleet on new
48% HD-X technology at YE2020
+30%
37.6
Instruments installed, with 93
180 HD-Xs (50%+ New) and 84 SR-Xs
+44%
17.6
22.9
& SP-Xs
12.2
Consumables Revenue growth in
45%
Approximate*
Q4 2020 vs. Q4 2019 with
utilization reverting to 55%+
15 16 17 18 19 20* 20*
NON-GAAP GAAP
Excl. Abbott & RADx Incl. Abbott & RADx
* Q4 2020 and FY 2020 information are preliminary, unaudited estimates and are subject to the Company’s normal quarter and
year-end close procedures. These procedures and the audit of the Company’s financial statements for the year ended December J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 20
31, 2020 are ongoing and could result in changes to such estimated information.2020 COMPELLING PROGRESS
TTM Revenue Stratification (Oct. 2019 to Sept. 2020)
Other
11% Services
6% 10% 25%
Products &
Geography 40% Customer Diseases 27%
Services
29% 63%
60% 60% 31% 38%
Q4’20*
GROWTH GROWTH GROWTH GROWTH
NA +26% Pharma / CROs +32% Neurology +10% Instruments +13%
Europe +30% Academia +12% Oncology** +138% Consumables +11% ~45%
Asia +13% Others +79% Accelerator +76% ~45%
Neurology back to 30-40% Growth in Q4*
* Q4 2020 and FY 2020 information are preliminary, unaudited estimates and are subject to the Company’s normal
quarter and year-end close procedures. These procedures and the audit of the Company’s financial statements for
the year ended December 31, 2020 are ongoing and could result in changes to such estimated information.
** Incl. Immunology & Inflammation;
All numbers exclude 1H FY19 $1M 1x Study revenue
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 212020 COMPELLING PROGRESS
Delivered 2020 Objectives Plus, Despite Headwinds
Neurology COVID Strategy Financials Technology
Despite COVID Serology EUA Abbott License FY Reported Revenue 100x Sensitivity
headwinds . . . Agreement Growth ~50% increase pathway
Antigen EUA defined and published
Double-digit growth AD Trials use of Non-GAAP Revenue*
RADx Contract QTRX biomarkers Growth ~20%
48% HD-X IB despite COVID
at YE 2020 Top-Payor Several Diagnostic
Surveillance Studies Accelerators across 93 HD-X placements
APAC Lab. Services COVID and Neurology (50%+ New Installs)
partnership and
expanded presence 84 New SR-X/SP-X
placements
* Excludes Abbott and RADx Revenue
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 222020 COMPELLING PROGRESS
Objectives 2021
RUO 2019-2024 CAGR 30-40% - Diagnostics Pre-Mature and Incremental . . .
Neurology COVID Immunology Financials Platform
Increases Biomarker Drive Antigen & Serology Expand Assay Menu & RUO 5Yr CAGR Operation Scale
penetration in Commercialization accelerate publication flow 30-40% Quanterix (OSQ)
Neuro Trials over 2019-2024
Deliver RADx Scale-Up 50 SP-X placements Define pathway to
65% HD-X IB Diagnostics deploy 100x Sensitivity
at YE 2021 Support Leading-Edge Progress SP-X towards (COVID and Neuro) in the field
COVID Research and platform of choice for Pre-mature and
Measurable progress develop novel solutions Liquid Biopsy LDTs Incremental Expand Di5 PPH
on Neuro Diagnostic Disruptive
Vertical & Payor – Expand Payor NIH – Payor – Pharma 105 HD-X placements Relationships
Pharma Drug Trials Surveillance Studies Longhauler & Drug Trials (60%+ New Installs)
140 New SR-X/SP-X
placements
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 23POWERING PRECISION HEALTH
Our mission and vision to power precision health
1 2
Therapies Prevention
Advocates – KOL’s - Agencies – Investors
INNOVATION PATIENTS
We are on a mission to change the way in which healthcare
Brain Health
is provided by giving researchers the ability to closely
examine the continuum from health to disease.
COVID
In order to make this vision a reality, we formed a
collaborative ecosystem by bringing together the most
experienced management team, renowned scientists, Immunology and Oncology
industry leading investors and expert advisors, all united
through the common goal of advancing the science of
Disruptive opportunities
precision health.
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 24POWERING PRECISION HEALTH
Value Creation & Disruptive Growth Accelerators
KOLs
1 Greater Purpose
Investors Pharma
2 PPH Ecosystem
FIVE STEPS TO
Think COMMERCIALIZING
CROs
Tanks
DISRUPTIVE
INNOVATION
3 Culture & Leadership
Operation Scale Q
Agencies Academics
• PPH Inside
4 Strategy Roadmap
1 Payors 2 • Efficiency & Capacity
• Product launches
Drug & Disease
• Org & infrastructure 5 Superb Execution
Therapy Prevention
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 25COVID Drugs
Anthony Fauci
Longhauler
Francis Collins
Other
Payors
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 26COVID Drugs
Anthony Fauci
Longhauler
Francis Collins
Leroy Hood
Contagion
Michael Milken Other Conference
Payors
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 27POWERING PRECISION HEALTH
Neurology poised for Value Creation Chain Reaction
Drug-Trials Penetration center-piece of near-term focus
Demonstrate Clinical
2 Validity & Utility
Imaging & Sample data
support Clinical Validity,
Biomarker Drug Development
0 Discovery 1 Biomarker Adoption
Utility and HECON
Access to Trial data
Research led by Currently underpenetrated accelerates and reduces
academia and Partnering with cost for Dx Clinical Study
pharma Pharma to accelerate adoption
(End-Points, Patient Stratification)
NfL pTau181 pTau217
Aβ42,Aβ40 tTau GFAP
Diagnostic
Path to Dx further fuels Drug
Development Biomarker Adoption in 3 Launch, Adoption
Drug Development & Reimbursement
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 28POWERING PRECISION HEALTH
Accelerators Driving Rapid Adoption for Transforming Drug
Development
Research Institutions Biopharma CROs & Other
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 29POWERING PRECISION HEALTH – BRAIN HEALTH
Serum Nf-L Powering Major MS Drug Trials
$22B Market – 16 drugs
Right R EL APSE
Drug?
EDSS 1.0 EDSS 3.0 EDSS 5.0 EDSS 7.0
No disability with Moderate Disability affects Essentially restricted
only minimal signs disability full daily activities to wheelchair
Phase III ASCLEPIOS I/II trials
Nf-L used as secondary endpoint, reduction after 3 months
APPROVED IN Q3 Approved in Q3 2020
Phase III OPERA I/II AND ORATORIO trials
Nf-L lowered to healthy
Ocrevus:
$1.75B sales, highest MS drug share in US of 40%
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 30POWERING PRECISION HEALTH – BRAIN HEALTH
AD Blood Biomarkers - Research to Clinical
Lilly & Quanterix Collaboration on Alzheimer’s Disease Biomarkers
Research
& Trials
< 0.5B TAM
Very early detection
16 yrs before dementia
Blood p-Tau 217 / 181 / NfL
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 31POWERING PRECISION HEALTH – BRAIN HEALTH
AD Blood Biomarkers - Research to Clinical
Lilly & Quanterix Collaboration on Alzheimer’s Disease Biomarkers
Research Diagnostics &
& Trials Health Screens
< 0.5B TAM ~$11B TAM
Very early detection Relevance to Alzheimer’s
16 yrs before dementia treatment
Blood p-Tau 217 / 181 / NfL CSF p-Tau 181 modulated by
aducanumab
Hope for therapeutic with donanemab
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 32POWERING PRECISION HEALTH – BRAIN HEALTH
AD Blood Biomarkers - Research to Clinical
Lilly & Quanterix Collaboration on Alzheimer’s Disease Biomarkers
Research Diagnostics &
& Trials Health Screens
< 0.5B TAM ~$11B TAM
Very early detection AD specificity & clinical Relevance to Alzheimer’s
16 yrs before dementia accuracy in Blood vs. PET treatment
Images & CSF spinal taps
Blood p-Tau 217 / 181 / NfL Blood p-Tau 181 / 217 CSF p-Tau 181 modulated by
aducanumab
Blood p-tau181 predicts
amyloid pathology & AD
Hope for therapeutic with donanemab
CSF PET Imaging
AD Diagnostics and Screening based on Health Advances Estimates and Report 2020 J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 33POWERING PRECISION HEALTH – BRAIN HEALTH
Recent excitement in liquid biopsy points to
future potential of “liquid MRI”
Liquid biopsy “Liquid MRI”
for screening for brain
JUN 2016 FDA approved first liquid biopsy test (lung cancer)
DEC 2019 Natera receives expanded Medicare coverage
for solid tumor test Approval of first Alzheimer’s
Drug likely will be the tipping
MAR 2020 Natera receives favorable Medicare point for similar value
reimbursement for organ transplant test acceleration and adoption
JUN 2020 acquires in a $1.4B deal
momentum
SEP 2020 acquires at $8.0B valuation
OCT 2020 acquires at $2.15B valuation
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 27POWERING PRECISION HEALTH – BRAIN HEALTH
Neurology Reimagined
CSF & PET Imaging Blood-based SIMOA Neuro Assays
Aβ42 tTau pTau181 Aβ42,Aβ40 tTau pTau181/217
Alzheimer's
Nf-L BDNF SNAP-25 Parkinson’s Nf-L BDNF SNAP-25
α-synuclein GDF-15 IL-6 Multiple Sclerosis α-synuclein GDF-15 IL-6
Traumatic Brain Injury
GFAP Neurogranin NPTX2 GFAP Neurogranin NPTX2
Lewy Body Dementia
S100b sTREM2 TDP43 S100b sTREM2 TDP43
Huntington’s
VILP-1 YKL-40 MMP-3 Stroke VILP-1 YKL-40 MMP-3
Aβ37/38/40 Osteopontin IGFBP7 ALS Aβ37/38 Osteopontin IGFBP7
FTD
NSE TRAIL NSE TRAIL
Developed in Serum and/or Plasma – Simoa catalog assay kits
Developed in Serum and/or Plasma – Simoa homebrew assays
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 35POWERING PRECISION HEALTH – COVID HIGH-DEFINITION
Roadmap to High-Definition picture of SARS-CoV-2 Infection
Symptoms
Appear
Quantitative Concentration
Antigen
Day 0 Days since infection Day 20
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 36POWERING PRECISION HEALTH – COVID HIGH-DEFINITION
Roadmap to High-Definition picture of SARS-CoV-2 Infection
Most Symptoms
contagious Appear
Quantitative Concentration
Antigen
Day 0 Days since infection Day 20
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 37POWERING PRECISION HEALTH – COVID HIGH-DEFINITION
Roadmap to High-Definition picture of SARS-CoV-2 Infection
Most Symptoms
contagious Appear
Quantitative Concentration
Pro-inflammatory
inflammatory
cytokines
Interferon
response Antigen
Day 0 Days since infection Day 20
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 38POWERING PRECISION HEALTH – COVID HIGH-DEFINITION
Roadmap to High-Definition picture of SARS-CoV-2 Infection
Most Symptoms
contagious Appear
Quantitative Concentration
Pro-inflammatory
inflammatory IgG
cytokines IgA IgM
Interferon
response Antigen
Day 0 Days since infection Day 20
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 39POWERING PRECISION HEALTH – COVID HIGH-DEFINITION
Roadmap to High-Definition picture of SARS-CoV-2 Infection
DETECTION WINDOW
Quantitative Concentration
Pro-inflammatory IgG
cytokines IgA IgM
Interferon
response Antigen
Conventional Sensitivity waterline of
detection conventional immunoassay
Day 0 Days since infection Day 20
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 40POWERING PRECISION HEALTH – COVID HIGH-DEFINITION
Roadmap to High-Definition picture of SARS-CoV-2 Infection
N E W T E S T I N G PA R A D I G M
Disruption Enabled By Ultra Sensitivity Digital ELISA
Quantitative Concentration
DETECTION WINDOW
Pro-inflammatory IgG
cytokines IgA IgM
Interferon
response Antigen
Day 0 Days since infection Day 20
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 41POWERING PRECISION HEALTH – COVID HIGH-DEFINITION
Roadmap to High-Definition picture of SARS-CoV-2 Infection
1 4 3 2
Innate Immune Response Antigen – EUA Submitted Serology – EUA Submitted NfL – Brain Health
Cytokine storm - Vaccines Asymptomatic, early detection, false +/-’s High Def - Early detection - Home care Loss of Taste & smell
Saliva, blood &, nasal + supply & quantitation Scaling lab for membership surveillance Brain fog
Risk Stratification –Immune fatigue $20M Award
N E W T E S TPPH
EUA NP approved
EUA Semi-Quant
I N G PA RADIGM
5 IRB’s Longhaulers
Major
Payor
Long-term brain health impact
Therapies Long Haulers
Disruption Enabled By Ultra Sensitivity Digital ELISA
Quantitative Concentration
DETECTION WINDOW
Pro-inflammatory IgG
cytokines IgA IgM
Interferon
response Antigen
Day 0 Days since infection Day 20
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 42POWERING PRECISION HEALTH – COVID HIGH-DEFINITION
Roadmap to High-Definition picture of SARS-CoV-2 Infection
1 4 3 2
Innate Immune Response Antigen – EUA Submitted Serology – EUA Submitted NfL – Brain Health
Cytokine storm - Vaccines Asymptomatic, early detection, false +/-’s High Def - Early detection - Home care Loss of Taste & smell
Saliva, blood &, nasal + supply & quantitation Scaling lab for membership surveillance Brain fog
Risk Stratification –Immune fatigue $20M Award
N E W T E S TPPH
EUA NP approved
EUA Semi-Quant
I N G PA RADIGM
5 IRB’s Longhaulers
Major
Payor
Long-term brain health impact
Therapies Long Haulers
Disruption Enabled By Ultra Sensitivity Digital ELISA
5 Comprehensive High-Definition Kinetic Picture – PPH Ecosystem
Quantitative Concentration
DETECTION WINDOW
Pro-inflammatory IgG
cytokines IgA IgM
Interferon
response Antigen
Mar. 31 Apr. 7 Apr. 14 Apr. 21 Apr. 28
2020 2020 2020 2020 2020
Day 0 Days since infection Day 20
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 43POWERING PRECISION HEALTH – COVID HIGH-DEFINITION
SARS-CoV-2 Infection Impacts Multiple Organ Systems
Digital protein biomarkers provide early detection of acute disease and monitoring longitudinal manifestations
Brain and CNS Nose and Throat
Neurodegeneration Loss of smell, sore throat
Nf-l, GFAP, Tau GM-CSF, IFNγ, IL-6, IL-18, TNFα
Immune System Heart and Blood Vessels
CRS & Adaptive Immunity Cardiac and vascular damage
IFNα, IFNγ, IL-2, IL-6, IP-10, MCP-1 Troponin I, Ang-2, Fibrinogen, VEGF
Serology
Lungs Gut
ARDS Nausea, Intestinal Inflammation
IL-4, IL-5, IL-13, IL-17A, MMP-9 IL-12p70, IL-23, TGFβ
Kidneys Liver
AKI, Intrarenal inflammation Liver damage
CRP, IL-1β, IL-8, IL-10, NGAL, TIMP-2 mIR-122, CRP, RANTES, TNFα
Fingers and Toes Systemic
Rash, Swelling Pain, Fever and Fatigue
INFγ, Inflammatory Cytokines CRP, Inflammatory Cytokines
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 44POWERING PRECISION HEALTH – COVID HIGH-DEFINITION
Diagnostic Entry Accelerated by COVID & RADx
ACCELERATORS GO-TO-MARKET
Expanding Mfg and building Capacity, Strategic focus on standing up at University /
Regulatory & Quality Capabilities Payors with On-Site CLIA labs
Established FDA Credibility & Enabling major Focus Pre & Asymptomatic testing &
Payor + Population Surveillance Studies Expand to Nasal/Oral Swab, Saliva, DBS
Builds distributed infrastructure to attract and Value Proposition - Accuracy, Price, High-
support future Neuro CDx Throughput, independent supply chain and
Home Collection and Pooling
COVID PPH Think Tank connecting dots for
Nextgen viruses and drug & vaccine efficacy
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 45POWERING PRECISION HEALTH – EMERGING IMMUNOLOGY & ONCOLOGY
Liquid Biopsy expanding into Proteomic
Prostate Pancreatic Brain Breast
Cancer Cancer Cancer Cancer
Only assay capable of LIF levels with Simoa Neurofilament Light Chain Protein Biomarkers
precise measurement of showed elevation in as Biomarker for Brain Measurement in
PSA following Pancreatic cancer Metastases CancerSEEK yielding
prostatectomy patients False Negative Results
Better correlation with Simoa’s ~700x lower
response than FDA- LLOQ holds the
approved CA19-9 marker potential for accurate
early detection
Al Roker Alex Trebek Bo Biden Angelina Jolie
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 46POWERING PRECISION HEALTH – DISRUPTIVE HIGH-GROWTH OPPORTUNITIES
Payor Relationships Hold Disruption Promise
Millions of
Members
Goal: Improve Outcomes
Early detection, remove cost,
lengthen life, add members
Oncology
Inflammation
Infectious disease
Neurology
Cardio
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 47POWERING PRECISION HEALTH – DISRUPTIVE HIGH-GROWTH OPPORTUNITIES
Payor Relationships Hold Disruption Promise
Millions of Massive Opportunity to Transform Healthcare
Members Five IRB’s Underway
Goal: Improve Outcomes
Early detection, remove cost, A
lengthen life, add members
Known Biomarkers
Oncology and Therapy
Inflammation DEPLOY NOW
Infectious disease MS, Diabetes, COVID
Neurology
Cardio
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 48POWERING PRECISION HEALTH – DISRUPTIVE HIGH-GROWTH OPPORTUNITIES
Payor Relationships Hold Disruption Promise
Millions of Massive Opportunity to Transform Healthcare
Members Five IRB’s Underway
Goal: Improve Outcomes
Early detection, remove cost, A B
lengthen life, add members
Known Biomarkers Known Biomarkers,
Oncology and Therapy No Therapy
Inflammation DEPLOY NOW FIND THERAPIES
Infectious disease MS, Diabetes, COVID Alzheimer’s,
Parkinson’s, ALS
Neurology
Cardio
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 49POWERING PRECISION HEALTH – DISRUPTIVE HIGH-GROWTH OPPORTUNITIES
Payor Relationships Hold Disruption Promise
Millions of Massive Opportunity to Transform Healthcare
Members Five IRB’s Underway
Goal: Improve Outcomes
Early detection, remove cost, A B C
lengthen life, add members
Known Biomarkers Known Biomarkers, Known Therapy,
Oncology and Therapy No Therapy No Biomarkers
Inflammation DEPLOY NOW FIND THERAPIES BIOMARKER
MS, Diabetes, COVID Alzheimer’s, DISCOVERY
Infectious disease
Parkinson’s, ALS Liquid Biopsies,
Neurology Long-term
Surveillance Study
Cardio
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 50PROTEOMICS DISRUPTION CATALYZING PRECISION HEALTH TRANSFORMATION
From Technology to Applications
Applications
and Services
Operating
Systems
Systems
CPUs
Strategic Applications
Data Analysis Customers and Services
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 51PROTEOMICS DISRUPTION CATALYZING PRECISION HEALTH TRANSFORMATION
From Technology to Applications
Applications
and Services
Operating Exact Sciences
Systems $16B VALUE
ACQUIRED
Thrive $2.5B
Systems
CPUs
Illumina
$48B VALUE
ACQUIRED
Strategic Applications Grail $8B
Genomics Data Analysis Customers and Services
Sequencers
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 52PROTEOMICS DISRUPTION CATALYZING PRECISION HEALTH TRANSFORMATION
From Technology to Applications
Applications
and Services
Operating Exact Sciences
Systems $16B VALUE
ACQUIRED
Thrive $2.5B
Systems
CPUs
Illumina
$48B VALUE
ACQUIRED
Strategic Applications Grail $8B
Genomics Data Analysis Customers and Services
Sequencers
Proteomics
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 53J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 54
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 55
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 56
1B 7B 0B 57B
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 571B 7B 20B 0B 57B 100B
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 58VISION AND STRATEGY FOR DISRUPTIVE VALUE CREATION
Compelling Thesis to Lead Proteomics into Precision Health Era
Execution Aspiration
2 to 3x Value Creation 10 to 15x Value Creation
RESEARCH & DISCOVERY D I A G N O S T I C S & H E A LT H S C R E E N S
$1B to $20B TAM $100B TAM
Validation: Pubs, Trials, Pharma Adoption Abbott, Siemens, Pharma Advances
2014-20 Rev: $0 - $85m; 55% CAGR* - Public Payor Acceptance for Cost / Outcome
COVID
Raised $350m; Valuation $30m to $2.0 B RADx NIH, RADx & FDA Ecosystem expansion
ST & LT Growth Catalysts ST & LT Growth Catalysts
• Increase penetration Neuro, COVID, Immuno • COVID EUA’s
• Menu expansion & drug / population trials • Neuro Tool Entry – Leverage COVID
• Scale consumables growth – New COO • Liquid Biopsy Entry (Partner or Vertical)
• Expand into upstream Discovery tools • Advance Payor “Outcome Leapfrog”
* 2017-2020 3Yr CAGR
* FY 2020 information are preliminary, unaudited estimates and are subject to the Company’s normal quarter
and year-end close procedures. These procedures and the audit of the Company’s financial statements for J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 59
the year ended December 31, 2020 are ongoing and could result in changes to such estimated information.Aspiration 2.0
DIGITAL HEALTH
TELEMEDICINE DIGITAL INTERCONNECTED CONTROL DIAGNOSIS COMMUNICATE HEALTHCARE
digital
biomarkers
BIOMARKER WATCH
Fitbit on Steroids!!
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 60Appendix
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 61Our Single Molecule Arrays (Simoa®) technology allows for the
ultimate sensitivity by detecting a single molecule
Traditional ELISA assay Simoa®
Millions of molecules needed to Single molecule needed to
reach detection limit reach detection limit
SUBSTRATE
Traditional (Analog) SiMoA (Digital)
0 pM 10 pM 0 aM 3.5 aM 350 aM 3.5 fM
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 622020 COMPELLING PROGRESS
Quanterix Product Offerings
INSTRUMENTS ASSAY KITS SERVICES
Bead based Planar
HD-X SR-X SP-X Consumables & Reagents Accelerator
List Price: $200k List Price: $75k List Price: $75k 400+ assays Contract research
311 Installed 175 Installed 35 Installed Homebrew kits Custom assay development
(149 HD-X, 162 HD-1)
Benchtop Benchtop Singleplex and Multiplex & reagent production
Fully automated Neuro Focused Onco Focused CLIA and LDT capabilities
Neuro Focused Drug Rescue
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 63POWERING PRECISION HEALTH – BRAIN HEALTH
Brain Diagnostic Health Roadmap
Application
Roadmap
MS Therapy AD Triage & TBI Monitoring & High-Definition
Monitoring Screening Return to Play Liquid MRI
TAM ~$0.5B ~$11B ~$0.5B ~$6B
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 64POWERING PRECISION HEALTH – COVID HIGH-DEFINITION
SIMOA supporting Leading-Edge COVID Research
Keys to developing Ultra-Sensitivity driven differentiated offering Long-Term COVID impact
Establishing biomarker
profile (serology,
cytokines, cardiac, neuro)
in Long-haulers
Measuring Type I
Interferon response
in prediction of
disease severity in
COVID19
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 65There are major LB applications across the disease continuum Neuro Diagnostics Market anticipated to also expand across these 5 Application Vectors . . .
POWERING PRECISION HEALTH – DISRUPTIVE HIGH-GROWTH OPPORTUNITIES
Disruptive Opportunities with High-Growth potential
Initial Quanterix
partnerships TAM
Opportunity Value of ultra-sensitivity
• Ability to assess previously undetectable
biomarkers
KOLs Population
• Unlock visibility into earlier disease states Major US
Health ~$5B
Investors Pharma Payor group
Assessment of large, • Non-invasive sample compatibility (low
population-level volume)
datasets
Think
CROs
Tanks
• Non-invasive and self-sampling
compatibility (e.g., finger prick, dried blood
spots) Major CRO
Decentralized Labs
Agencies Academics
• More frequent & robust Longitudinal Data ~$5B
(virtual) Trials
Payors • Higher Subject Compliance & throughput RADx
At-home assessment of (Enhanced Speed & Lower Cost)
subject health status Funding
• Inclusion of Under-Served Populations
J.P. Morgan Healthcare Conference 2021 | Jan. 13, 2021 | 67You can also read
